Chimerix Announces Incentive Award Under Nasdaq Listing Rule 5635(c)(4)

DURHAM, NC, Aug. 30, 2024 (GLOBE NEWSWIRE) — Chimerix (NASDAQ:CMRX) today announced that on August 20, 2024, the Compensation Committee of the Board of Directors of Chimerix granted an incentive award to a new employee of non-statutory stock options to purchase up to an aggregate of 150,000 shares of Chimerix common stock. The Compensation Committee of the Board of Directors of Chimerix approved the award as employment incentive material for the new employee in accordance with Nasdaq Listing rule 5635(c)(4).

The stock options have an exercise price per share equal to Chimerix’s closing price on the date of grant. The stock options have a term of 10 years and are distributed over four years, with one-quarter distributed on the first anniversary of the date of employment and the remaining three-quarters distributed over the next three years in equal monthly installments. The stock options are subject to the terms of Chimerix’s 2024 Equity Incentive Plan, but were granted outside of the 2024 Equity Incentive Plan.

Chimerix is ​​a biopharmaceutical company with a mission to develop medicines that meaningfully improve and extend the lives of patients with terminal diseases. The company’s most advanced clinical development program, ONC201, is in development for H3 K27M mutant glioma. The company is conducting Phase 1 dose escalation studies of ONC206 to evaluate safety and PK data.

CONTACTS:
Will O’Connor
Stern Investor Relations
212-362-1200
[email protected]
[email protected]